UHAL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
UHAL is not a good buy right now for an impatient investor. The near-term technical setup is weakening (bearish MACD, price below pivot and sitting near support), options flow is skewed defensively (heavy put volume), and the next earnings event (2026-02-09 after hours) adds near-term headline risk while profitability trends are deteriorating. Despite one bullish analyst initiation and a post-market bounce, the risk/reward is not attractive for an immediate entry.
Price/levels: Post-market 56.55 is below the pivot (57.568) and only modestly above S1 (56.117), meaning the stock is trading in a fragile zone where a small sell-off can break support toward S2 (55.22). Momentum: MACD histogram is negative (-0.0772) and expanding lower, signaling bearish momentum building. RSI(6) at 47.685 is neutral, not showing an oversold bounce setup. Moving averages are converging, suggesting indecision/chop rather than a clean uptrend. Near-term bias: slightly bearish-to-neutral unless price reclaims the pivot (~57.6) and holds above it.
Analyst initiation (Vertical Research) with Buy and $80 target provides a positive narrative and potential valuation re-rate support.
Post-market +2.09% suggests some dip-buying interest after the regular-session decline.
Low-ish implied volatility (low IV rank/percentile) can support risk-defined bullish structures if sentiment improves.
Weakening momentum: bearish MACD expansion and price below pivot increases odds of a support test/break (S1 56.117, then S2 55.22).
Options flow is defensive: very high put-call volume ratio (6.
implies near-term hedging/bearish positioning.
Earnings catalyst ahead: QDEC 2025 earnings on 2026-02-09 (AH) with an EPS estimate of -0.24 increases event risk.
Fundamentals show margin and profit compression (see financials), which can cap upside until trends stabilize.
News flow is mostly promotional/operational (propane availability) rather than a clear earnings/upside catalyst.
Latest reported quarter: 2026/Q2. Revenue rose to $1.720B (+3.73% YoY), but profitability deteriorated sharply: Net income fell to $105.55M (-43.50% YoY) and EPS dropped to $0.54 (-43.16% YoY). Gross margin declined to 22.53% (-9.15% YoY), showing margin compression. Growth is present at the top line, but earnings quality and margins are moving the wrong way—this is a key reason the stock doesn’t screen as an immediate buy.
Recent trend: Limited coverage in the provided data; the key change is a single initiation (2025-11-03) from Vertical Research (Jeffrey Kauffman) at Buy with an $80 price target. Wall Street pros view (based on this data): upside implied vs current price and a supportive narrative around the business. Cons view: the market will likely focus on shrinking earnings/margins and the upcoming earnings event risk; without improving profitability, the $80 target may be harder to justify in the near term. Trading trends: Hedge funds and insiders are neutral; no strong accumulation signal. Influential/politician activity: No recent congress trading data available.
